Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2022 16:05 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2...
February 22, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
February 10, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for...
February 09, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
February 02, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications

BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir...
January 07, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir...
January 03, 2022 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
December 17, 2021 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the...
December 14, 2021 16:30 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527 In addition to monotherapy evaluation,...
November 22, 2021 07:00 ET | Source: Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...